8-K: Vir Bio Licenses Hepatitis Delta Treatment Rights to Norgine

Vir Biotechnology has granted Norgine Pharma UK an exclusive license for commercial rights to its investigational chronic hepatitis delta treatment in Europe, Australia, and New Zealand, securing an initial EUR 55 million and up to EUR 495 million in milestones.

Summary

• Vir Biotechnology (Vir Bio) and Norgine Pharma UK Limited (Norgine) entered into a License Agreement on December 16, 2025, for commercial rights to the combination of tobevibart and elebsiran for chronic hepatitis delta (CHD).
• Norgine receives exclusive commercial rights for the combination in Europe, Australia, and New Zealand, while Vir Bio retains rights in the United States and other international markets outside the Greater China Territory.
• Vir Bio will receive an initial reimbursement of development costs of EUR 55 million from Norgine.
• Vir Bio is eligible to receive up to EUR 495 million in clinical, regulatory, and sales milestones, along with tiered, mid-teen to high-twenties percent royalties on net sales in the Norgine Licensed Territory.
• Clinical development costs for Vir Bio's ECLIPSE registrational program (ECLIPSE 1, 2, and 3) will be shared, with Norgine contributing approximately 25% of go-forward external costs.
• The closing of the transaction for certain jurisdictions is subject to Norgine receiving regulatory approval from applicable authorities.
• Forty-eight week data from the SOLSTICE Phase 2 clinical trial showed 66% (21/32) of participants with CHD receiving the combination achieved and sustained HDV RNA target not detected (TND) at 48 weeks.
• Approximately 90% (29/32) of participants achieved reduction in hepatitis B surface antigen (HBsAg) to values <10 IU/mL by Week 48.
• Alanine aminotransferase (ALT) was normalized in 56% (18/32) of participants by Week 48.
• The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations.
• Enrollment for ECLIPSE 3, a Phase 2b head-to-head trial comparing the combination with bulevirtide, has been completed.
• The agreement is expected to extend Vir Bio's current cash, cash equivalents, and investments into the fourth quarter of 2027.

Sentiment

Score: 8

Explanation: The filing details a significant licensing agreement with substantial financial terms (upfront payment, milestones, royalties, cost-sharing) and positive clinical trial data for a promising drug candidate in an area of high unmet medical need. This significantly de-risks the program and extends the company's financial runway.

Positives

• Secured an initial reimbursement payment of EUR 55 million from Norgine.
• Eligible to receive up to EUR 495 million in clinical, regulatory, and sales milestones.
• Will receive tiered, mid-teen to high-twenties percent royalties on net sales in the Norgine Licensed Territory.
• Norgine will contribute approximately 25% of go-forward external clinical development costs for the ECLIPSE registrational program, reducing Vir Bio's financial burden.
• The agreement is expected to extend Vir Bio's cash, cash equivalents, and investments into the fourth quarter of 2027.
• Positive 48-week data from the SOLSTICE Phase 2 trial demonstrated 66% (21/32) of participants achieved HDV RNA target not detected (TND).
• Approximately 90% (29/32) of participants in the SOLSTICE trial achieved significant HBsAg reduction.
• The combination treatment was well-tolerated, with no severe adverse events or treatment-related discontinuations.
• Completion of enrollment for ECLIPSE 3, a key Phase 2b head-to-head trial designed to support access and reimbursement in Europe and other key geographies.
• The combination has received Breakthrough Therapy and Fast Track designations by the U.S. FDA, and Priority Medicines (PRIME) and orphan drug designations by the European Medicines Agency (EMA).

Risks

• Unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events.
• Risks of unexpected costs, delays, or other unexpected hurdles in drug development.
• Difficulties in collaborating with other companies, some of whom may be competitors or have divergent interests, and uncertainty as to whether the benefits of collaborations can ultimately be achieved.
• Challenges in accessing manufacturing capacity for the drug combination.
• Clinical site activation rates or clinical enrollment rates that are lower than expected.
• The timing and outcome of interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals.
• Successful development and/or commercialization of alternative product candidates by competitors, as well as changes in expected or existing competition.
• Geopolitical changes or other external factors impacting operations or markets.
• Unexpected litigation or other disputes.
• Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product.
• Results in early-stage clinical studies may not be indicative of full results or results from later-stage or larger-scale clinical studies and do not ensure regulatory approval.

Future Outlook

Vir Bio expects the combination of tobevibart and elebsiran to be a potentially first-of-its-kind therapy for chronic hepatitis delta (CHD), addressing significant unmet patient needs. The company anticipates topline data for all three ECLIPSE trials in the first quarter of 2027. The licensing agreement with Norgine is expected to extend Vir Bio's cash runway into the fourth quarter of 2027.

Management Comments

• "We believe Norgine has the ideal expertise and reach in key international markets to maximize the impact of our investigational treatment for CHD."
• "People living with this devastating disease deserve efficacious, safe and convenient treatment options."
• "This agreement advances our commitment to sustainably develop and commercialize the tobevibart and elebsiran combination treatment globally while advancing our innovative clinical pipeline."
• "We are excited to collaborate with Vir Biotechnology to advance care in CHD and improve patient access to this innovative therapy." (Janneke van der Kamp, CEO, Norgine)

Industry Context

Chronic Hepatitis Delta (CHD) is recognized as the most severe form of chronic viral hepatitis, leading to rapid progression to cirrhosis, liver failure, and liver-related death, with limited approved treatments globally. The combination of tobevibart and elebsiran is positioned as a potentially first-of-its-kind therapy, aiming to disrupt the viral lifecycle through multiple mechanisms. This strategic partnership with Norgine, a leading European specialty pharmaceutical company, leverages Norgine's established expertise and market reach in Europe, Australia, and New Zealand to address this significant unmet medical need, while allowing Vir Bio to focus on commercialization in the U.S. and other major international markets.

Comparison to Industry Standards

• The ECLIPSE 3 trial is designed as a Phase 2b head-to-head study evaluating tobevibart and elebsiran against bulevirtide in bulevirtide-naive patients, directly benchmarking its efficacy against an existing therapy for CHD in some regions.
• The combination has received Breakthrough Therapy and Fast Track designations from the U.S. FDA, and Priority Medicines (PRIME) and orphan drug designations from the European Medicines Agency (EMA), indicating regulatory recognition of its potential to offer significant advantages over existing treatments for a serious condition.
• The 48-week data from the SOLSTICE trial, showing 66% HDV RNA TND and 90% HBsAg reduction, represents strong efficacy in a disease with high unmet needs and limited therapeutic options.

Stakeholder Impact

• Shareholders: Positive impact due to significant non-dilutive funding, reduced R&D costs, extended cash runway, and validation of the drug candidate's potential, which could lead to increased share price.
• Patients: Potential for a new, efficacious, safe, and convenient treatment option for chronic hepatitis delta, a severe disease with limited therapies.
• Employees: Continued development and potential commercialization of a key pipeline asset, ensuring job stability and growth opportunities.
• Partners (Norgine): Gains exclusive commercial rights in key territories for a promising therapy, expanding its specialty care portfolio.
• Regulatory Authorities: The positive clinical data and Breakthrough Therapy/PRIME designations suggest a potentially important new therapy for review.

Next Steps

• Norgine to receive regulatory approval from applicable authorities for the closing of the transaction in certain jurisdictions outside the United States.
• Vir Bio plans to file the full text of the Agreement as an exhibit to its Annual Report on Form 10-K for the quarter and year ending December 31, 2025.
• Continued clinical development of the ECLIPSE registrational program (ECLIPSE 1, 2, and 3).
• Anticipated topline data for all three ECLIPSE trials in the first quarter of 2027.

Key Dates

Recommendation

The licensing agreement provides substantial non-dilutive funding (EUR 55 million upfront, up to EUR 495 million in milestones, plus royalties) and significantly de-risks the development of a key asset by sharing 25% of future clinical costs. This extends the company's cash runway into Q4 2027. Coupled with compelling 48-week Phase 2 clinical data showing high rates of viral suppression and HBsAg reduction with a favorable safety profile for a severe disease with high unmet needs, this filing presents a very strong positive outlook for Vir Biotechnology. The strategic partnership with Norgine also enhances the global commercialization potential.

Keywords

Vir Biotechnology, Norgine Pharma, Hepatitis Delta, CHD, tobevibart, elebsiran, License Agreement, Biotechnology, Pharmaceuticals, Clinical Trials, ECLIPSE program, SOLSTICE trial, HDV RNA, HBsAg, Liver Disease, Drug Development, Commercialization